Dr. David Henry: It Just Keeps Getting Better and Better in Myeloma

Interview by L Scott Zoeller. 2012 Jan 25, David Henry, MD

To mark 2011, we have asked our distinguished OncologySTAT Advisory Board Members to choose their top story of the year. In this interview, Dr. David Henry discusses his choice for this year in myeloma. OncologySTAT: In your view, which development in 2011 could have the most significant impact in oncology?Dr. Henry: I’d like to focus on multiple myeloma as very exciting progress continues to be made in this area. Twenty-five years ago the median overall survival (OS) was a year for patients with...

NOT A MEMBER?

Registration is FREE

  • Up-to-date oncology news
  • Journal article summaries
  • Commentaries and interviews
  • Drug and interactions database
  • Chemotherapy regimens
  • Daily e-newsletters

 

Meet Our Experts

Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.

Editors' Choice

Everolimus Plus Tamoxifen Improves Survival in Metastatic Breast Cancer

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
  • Forgot your password?
    Not a member? Free registration